CUE BIOPHARMA INC's ticker is CUE and the CUSIP is 22978P106. A total of 64 filers reported holding CUE BIOPHARMA INC in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $440,533 | -17.5% | 191,536 | +30.9% | 0.00% | – |
| Q2 2023 | $534,090 | -19.0% | 146,326 | +24.7% | 0.00% | – |
| Q1 2022 | $659,000 | -24.1% | 117,327 | +40.8% | 0.00% | – |
| Q4 2021 | $868,000 | -28.9% | 83,321 | -11.9% | 0.00% | – |
| Q3 2021 | $1,220,000 | +8.8% | 94,543 | -1.8% | 0.00% | – |
| Q2 2021 | $1,121,000 | -10.5% | 96,245 | -6.3% | 0.00% | – |
| Q1 2021 | $1,252,000 | -29.7% | 102,669 | -27.9% | 0.00% | -100.0% |
| Q4 2020 | $1,781,000 | -16.3% | 142,361 | +0.6% | 0.00% | 0.0% |
| Q3 2020 | $2,129,000 | -40.0% | 141,450 | -2.3% | 0.00% | 0.0% |
| Q2 2020 | $3,550,000 | +189.1% | 144,838 | +67.3% | 0.00% | 0.0% |
| Q1 2020 | $1,228,000 | -40.9% | 86,559 | -33.8% | 0.00% | 0.0% |
| Q4 2019 | $2,077,000 | +252.0% | 130,779 | +86.9% | 0.00% | – |
| Q3 2019 | $590,000 | +3.5% | 69,954 | +10.4% | 0.00% | – |
| Q2 2019 | $570,000 | – | 63,349 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 829,042 | $9,376,000 | 5.61% |
| P.A.W. CAPITAL CORP | 120,000 | $1,357,000 | 1.24% |
| Nantahala Capital Management | 2,539,700 | $28,724,000 | 1.01% |
| Slate Path Capital LP | 1,483,619 | $16,780,000 | 0.88% |
| SANDERS MORRIS HARRIS LLC | 359,113 | $4,416,000 | 0.76% |
| APOGEM CAPITAL LLC | 62,295 | $705,000 | 0.46% |
| Robertson Stephens Wealth Management, LLC | 478,500 | $5,411,000 | 0.46% |
| Bleichroeder LP | 200,000 | $2,262,000 | 0.35% |
| ADVISORY RESEARCH INC | 257,225 | $2,909,000 | 0.23% |
| Granite Point Capital Management, L.P. | 110,000 | $1,244,000 | 0.21% |